GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (OTCPK:CNVVY) » Definitions » Valuation Rank

CNVVY (ConvaTec Group) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is ConvaTec Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


ConvaTec Group Valuation Rank Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


ConvaTec Group Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, 7th Floor, Paddington, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.